

# NYRx Notice to Pharmacies: Sodium Glucose Co-Transporter-2 Inhibitors

---

May 1, 2025

NYRx, the Medicaid pharmacy program, is sharing this notice with pharmacies to inform them of important therapeutic duplication information when submitting claims for Sodium Glucose Co-Transporter-2 inhibitors (SGLT-2 inhibitors):

- NYRx covers medically necessary, FDA-approved drugs when prescribed according to the FDA-approved package label, compendia-supported use, or aligned with peer-reviewed clinical practice guidelines.
- NYRx does not cover more than one SGLT-2 inhibitor or more than one strength of the same SGLT-2 inhibitor at a time. To reduce overutilization, stockpiling, and/or diversion of drugs, pharmacies will receive a rejection when submitting claims for more than one SGLT-2 inhibitor or more than one strength of the same SGLT-2 inhibitor while the patient still has greater than a 7-day supply of a current fill remaining.

**Note:** If a prescriber determines a need to switch the patient's treatment or dose while the patient still has greater than a 7-day supply of a current fill remaining, the prescriber may request a prior authorization from the NYRx Clinical Call Center.

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at [NYRxEO@primetherapeutics.com](mailto:NYRxEO@primetherapeutics.com) from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.